Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
NCT01147068
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
392
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
Interventions
BIOLOGICAL:
0.5mL Intramuscular Injection
Sponsor
Protein Sciences Corporation